23andMe CEO Anne Wojcicki files proposal to take company private as stock craters
Healthy Returns: Here’s what GLP-1s are being tested for beyond weight loss, diabetes
GEHC gives reasons to look beyond temporary China woes and shares reverse higher
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Lost in the market's sharp rotation out of tech stocks is a really bullish call on major banks
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
Neuralink rival Synchron's brain implant now lets people control Apple's Vision Pro with their minds
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
